PCM
ONCE

Palisade Capital Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Palisade Capital Management’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-11,200
Closed -$673K – 559
2016
Q3 		$673K Buy
+11,200
New +$646K 0.02% 460

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Palisade Capital Management's ONCE Position: Q4 2016 in Review

Palisade Capital Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2016, closing a stake of 11,200 shares — an estimated $673K sold.

Palisade Capital Management first reported a position in ONCE in Q3 2016 and held it in 1 quarter. The position peaked at $673K in Q3 2016. 119 funds tracked by Wall St. Rank hold ONCE as of Q4 2016.

  • Palisade Capital Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Palisade Capital Management sold 11,200 Spark Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $673K.
  • Palisade Capital Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2016 and held it in 1 quarter.
  • Palisade Capital Management's Spark Therapeutics, Inc. Common Stock position peaked at $673K in Q3 2016.
  • 119 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Palisade Capital Management's 13F filing for Q4 2016, filed 31 Jan 2017.